Emergent Biosolutions INC Form 4 insider transactions

An Emergent BioSolutions executive reported the acquisition of stock options and the disposition of common stock for tax purposes.

Emergent BioSolutions' CFO, Richard S. Lindahl, disposed of 683 common shares to cover tax liabilities related to restricted stock unit vesting.

Emergent BioSolutions' SVP, General Counsel, and Corporate Secretary, Jessica Perl, reported a future transaction on February 9, 2026, involving the disposal of 918 common shares to cover tax obligations from restricted stock unit vesting.

Emergent BioSolutions EVP Coleen Glessner's performance stock units, tied to cumulative revenue and adjusted EBITDA, vested at only 25% of their target for the 2023-2025 period.

Emergent BioSolutions' SVP, Products Business, Paul Anthony Williams, vested performance stock units at a 25% payout factor, receiving 8,655 shares and disposing of 1,022 for taxes.

Emergent BioSolutions SVP William Hartzel's performance stock units vested at 25% of target, resulting in a net acquisition of 1,922 shares after tax withholding.

Emergent BioSolutions' CFO, Richard S. Lindahl, reported a reduction in performance stock unit awards and shares withheld for tax purposes.

Emergent BioSolutions' SVP, R&D, CMO, Simon C. Lowry, disposed of 3,543 shares of common stock to cover tax liabilities from restricted stock unit vesting.

Emergent BioSolutions Inc. Director Richard Ronald reported exercising stock options and subsequently selling a net of 7,100 common shares.

Emergent BioSolutions SVP William Hartzel reported a future disposal of 610 common shares on November 11, 2025, to cover tax obligations from restricted stock unit vesting.

Emergent BioSolutions Director Donald W. DeGolyer sold 17,801 shares of common stock at a weighted average price of $10.54 to cover tax obligations related to RSU vesting.

Emergent BioSolutions Inc. Director Sujata Tyagi Dayal sold 8,552 shares of common stock at $10.00 per share under a Rule 10b5-1 trading plan.

Emergent BioSolutions' EVP and CFO, Richard S. Lindahl, filed a Form 4 reporting a pre-planned disposition of 4,995 common shares on October 15, 2025, to cover tax obligations related to restricted stock unit vesting under a Rule 10b5-1 plan.

Coleen Glessner, EVP of Quality & Ethics at Emergent BioSolutions Inc., sold 30,608 shares of common stock for $10.00 per share on October 7, 2025, under a pre-arranged 10b5-1 trading plan.

An Emergent BioSolutions director sold 7,086 shares of common stock at $8.87 per share to cover tax obligations from RSU vesting.

Emergent BioSolutions Director Donald W. DeGolyer sold 7,844 shares of common stock at $8.6475 per share to cover tax obligations from vested RSUs.

William Hartzel, SVP of Bioservices at Emergent BioSolutions Inc., disposed of 4,263 shares of common stock at $7.36 per share to cover tax liabilities associated with restricted stock unit vesting.

Emergent BioSolutions Inc.'s SVP of Bioservices, William Hartzel, disposed of 1,167 shares of common stock on June 8, 2025, to cover tax obligations related to the vesting of restricted stock units.

Emergent BioSolutions Inc. EVP Coleen Glessner reported a routine disposition of 1,249 shares of common stock to cover tax obligations related to restricted stock unit vesting.

Paul Anthony Williams, SVP of Products Business at Emergent BioSolutions Inc., reported the disposition of 464 common shares to cover tax liabilities related to restricted stock unit vesting.

Emergent BioSolutions' EVP and CFO, Richard S. Lindahl, reported the disposition of 2,733 shares of common stock to cover tax obligations related to restricted stock unit vesting.

Emergent BioSolutions Inc. Director Keith Katkin sold 7,844 shares of common stock on May 23, 2025, at a weighted average price of $6.3 per share, to satisfy tax obligations related to RSU vesting.

Emergent BioSolutions' CEO, Joseph Papa, recently acquired 60,000 shares of the company's common stock at an average price of $5.83 per share.

Director Richard Ronald reports acquisition of restricted stock units and stock options in Emergent BioSolutions, along with disposal of existing holdings.

Director Marvin L. White reports the acquisition of restricted stock units and stock options in Emergent BioSolutions Inc. on April 30, 2025.

Director Neal Franklin Fowler reports acquisition of 34,403 restricted stock units and 15,824 stock options, along with disposal of 135,503 common stock shares.

Director Kathryn C. Zoon reports the acquisition of restricted stock units and stock options in Emergent BioSolutions Inc.

Director Sujata Tyagi Dayal reports the acquisition of restricted stock units and stock options in Emergent BioSolutions Inc.

Director Keith Katkin receives stock options and restricted stock units from Emergent BioSolutions as part of annual compensation for board and committee service.

Director Zsolt Harsanyi received stock options and restricted stock units (RSUs) from Emergent BioSolutions on April 30, 2025, as part of the company's stock incentive plan.